This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
by Zacks Equity Research
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
BMYNegative Net Change INCYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
by Ahan Chakraborty
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Three Genomics Stocks Worth Tracking This Year
by Ekta Bagri
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
ILMNNegative Net Change BEAMNegative Net Change PACBNegative Net Change WVENegative Net Change CRSPNegative Net Change SANAPositive Net Change
biotechnology biotechs cell-therapy gene-therapy genetics genomics medical pharmaceuticals thematic
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
REGNNegative Net Change SNYPositive Net Change GILDPositive Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Intellia Stock Declines Around 55% in 3 Months: Here's Why
by Zacks Equity Research
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
REGNNegative Net Change ANIPNegative Net Change CRMDPositive Net Change NTLANegative Net Change
biotechs
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
by Zacks Equity Research
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
SNYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change MGNXPositive Net Change
biotechs medical pharmaceuticals
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
by Ahan Chakraborty
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
by Zacks Equity Research
Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
ANIPNegative Net Change CRMDPositive Net Change AXSMPositive Net Change CSTLNegative Net Change
biotechs
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
by Ekta Bagri
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
REGNNegative Net Change ABBVNegative Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III
by Sundeep Ganoria
Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
by Zacks Equity Research
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
REGNNegative Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Up 78% in 6 Months: Here's What You Need to Know
by Zacks Equity Research
Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.
INSMPositive Net Change ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs
Here's How AbbVie's Neuroscience Portfolio Is Aiding Top-line Growth
by Sundeep Ganoria
ABBV's neuroscience franchise now drives more than 17% of revenues, with strong Botox, Vraylar and migraine drug sales fueling double-digit growth.
BIIBPositive Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
by Zacks Equity Research
REPL shares soar 131.1% over the past three months after the FDA accepts its resubmitted BLA for the RP1/Opdivo combo in advanced melanoma.
BMYNegative Net Change ANIPNegative Net Change CRMDPositive Net Change REPLNegative Net Change
biotechs
RARE Rises on Completion of Rolling Submission for AAV Gene Therapy
by Zacks Equity Research
Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.
ANIPNegative Net Change RARENegative Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechs
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?
by Kanishka Das
Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.
BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
by Zacks Equity Research
Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.
NVOPositive Net Change VNDANegative Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
by Ekta Bagri
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
BMYNegative Net Change PFEPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
by Ekta Bagri
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
BMYNegative Net Change PFEPositive Net Change MRKNegative Net Change AMGNNegative Net Change
biotechnology biotechs dividend-yield medical pharmaceuticals
Can Amgen's MariTide Take on Leaders in the Obesity Space?
by Zacks Equity Research
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.
RARENegative Net Change CRMDPositive Net Change MREOPositive Net Change CSTLNegative Net Change
biotechs
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
by Sundeep Ganoria
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
JNJNegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals vaccines
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
by Zacks Equity Research
KYTX's shares surge after positive phase II data showed its CAR T miv-cel delivered major mobility gains in stiff person syndrome.
ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change KYTXNegative Net Change
biotechs
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
by Sundeep Ganoria
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
ALTNegative Net Change MCRBPositive Net Change IBRXPositive Net Change
biotechs medical
Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?
by Zacks Equity Research
Ocugen rises 75% YTD as it advances three gene therapies, with multiple phase II/III readouts and filings lined up for 2026.
ANIPNegative Net Change CRMDPositive Net Change CSTLNegative Net Change OCGNPositive Net Change
biotechs